To The Moon

2024 American Association of Cancer Research Annual Meeting (AACR 2024) will be held from April 5-10, 2024, in San Diego, United States. As the focal point of the cancer research community globally, countless latest scientific and medical studies in tumor field are first published here every year. In AACR 2024, one study of drug candidate GT0486 and two pre-clinical studies (including an anti-PD-1/ALK-1 bispecific antibody Nivo813 and a molecular glue GT19870) from Kintor Pharma are selected. It demonstrates high research and development value of drug and pre-clinical studies, also signifies that the company’s innovative capabilities and potential for drug development have been internationally recognized. The abstracts are available on AACR’s official website. Abstracts： GT0486（mTORC1/2）

Suzhou, 13 March, 2024 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announces that Kintor and its cooperative partner had published an article named MYC Induces CDK4/6 Inhibitors Resistance by Promoting pRB1 Degradation in a subsidiary journal of Nature—Nature Communications (Impact factor: 16.6). Nature Communications is one of the top journals in biology field and is classified as Q1 in several categories, representing a leading research level in the world. The study shows that target c-Myc molecular glue compound has great potential, which could provide more directions for overcoming resistance issues of CDK4/6 inhibitors in various tumor fields. Issue This

Suzhou, October 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the results of the Phase Ib/II clinical trial of ALK-1 antibody GT90001 combined with PD-1 antibody nivolumab in the treatment of advanced hepatocellular carcinoma (HCC) were published online by the well-known journal BMC Medicine (Impact factor: 11.806). The results showed that this combination regimen is well-tolerated and has promising anti-tumor activity in patients with recurrent advanced HCC, with a confirmed overall response rate (ORR) of 30% and a remarkable long-tail effect. https://doi.org/10.1186/s12916-023-03098-w HCC is a common pathological type of liver cancer. Th

Suzhou, August 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma” or “the company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2023 interim results and released an update on its recent business highlights.       2023 Interim Results Highlights ● Kintor Pharma has steadily advanced the global clinical development, with the dermatology pipeline achieving several milestones. The company has completed the patient enrollment in the Phase III clinical trial of KX-826 for male androgenetic alopecia (AGA) in China, and the top-line data is expected to be released in the fourth quarter of 2023. The Phase III clinical trial of KX-826 for female AGA in China and the Phase I

Suzhou, July 19, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today. The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023.  The Long-term Safety Trial is a multi-center, open-label Phase III clinical trial, which involves a total of 16 clinical research centers in China, with P

Suzhou, May 11, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia (“AGA”) in the US has been completed successfully. The results are statistically and clinically meaningful, and demonstrated a favorable safety profile. The company is preparing for subsequent FDA meetings on the results of the Phase II clinical trial, and intends to commence Phase III clinical trial in the US/globally. Results of the Phase II clinical trial showed that KX-826 promotes hair growth compared to baseline and demonstrated statistical and clinically meaningful as measured b

Suzhou, April 14, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the first patient enrollment in Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera (PROTAC) compound GT20029 in China for the treatment of male androgenetic alopecia (AGA). GT20029 is the world’s first topical PROTAC compound which entered the Phase II clinical stage. The Phase II clinical trial is a multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of GT20029 for treating male AGA adults in China. Kintor Pharma plans to enroll a total of 180 male AGA pa

Suzhou, March 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults. The Phase III clinical trial is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy and safety of 5mg (0.5% concentration) twice daily (BID) KX-826 for treating male AGA adults in China. Professor Zhang Jianzhong from Peking University People's Hospital and Professor Yang Qinping from Huash

Suzhou, February 10, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. Phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound. The data showed GT20029 was safe, well tolerated and had good pharmacokinetic characteristics in healthy subjects as well as subjects with androgenetic alopecia (AGA) or acne. GT20029 is the first topical PROTAC compound in the world which has completed Phase I clinical trial in both China and the U.S..  This is a randomized, double-blind, placebo-controlled, parallel group, dose esc

Suzhou, August 20, 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company’s stock has been included in the Hang Seng Composite Index, effective September 6, 2021. Hang Seng Composite Index (HSCI) is one of the important indexes in the Hong Kong equity market. This index offers a comprehensive Hong Kong market benchmark that covers the top 95th percentile of the total market capitalization of companies listed on the Main Board of the Stock Exchange of Hong Kong. Adopting the free-float-adjusted market capitalization methodology, the HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks. Dr. Youzhi To